Navigation Links
Phosphagenics Signs Research Agreement with the Agricultural Research Service
Date:5/20/2013

MELBOURNE, Australia, May 20, 2013 /PRNewswire/ --

  • Collaboration with the U.S. Department of Agriculture's (USDA) Agricultural Research Service (ARS) in treatment of mastitis
  • Major global market opportunity
  • Trials to begin in the second half 2013

Australian drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate with the U.S. Department of Agriculture's (USDA) Agricultural Research Service (ARS) to develop and trial products targeting the serious bacterial infection mastitis in dairy cows.  ARS is the USDA's chief intramural scientific research agency.

Under the agreement, Phosphagenics and ARS will formulate and evaluate products containing active ingredients in combination with the Company's TPM® delivery technology to enable superior absorption and efficacy. The products will include the formulation previously trialed by Phosphagenics with good results, as well as a formulation containing a Vitamin D derivative.

A preliminary study conducted by ARS in 2012 demonstrated that directly infusing the Vitamin D derivative into infected quarters of the mammary gland in infected dairy cows was able to significantly lower bacteria counts and clinical symptoms of mastitis.  The study also showed that cows treated with the derivative exhibited superior milk production.

The trials will begin mid-2013 and will be conducted in the U.S. by ARS.  Researchers will examine the effects and efficacy of the TPM® formulated products delivered via intra-mammary infusion using a protocol developed by ARS.  

Phosphagenics CEO, Dr Esra Ogru , said mastitis typically affected around 15% of the world's dairy herd at any given time.  In the USA alone, economic losses resulting from this infection are estimated at US$2 billion per annum.

"This is a significant problem for farmers worldwide as it affects milk quantity and quality," Dr Ogru said.

"Current standard of care for mastitis is antibiotic treatment, but there are widespread concerns globally around antibiotic resistant bacteria.  It is important to develop new therapeutics that bypass these problems and that are also effective."

Phosphagenics' proprietary TPM® delivery technology enables the superior absorption of key active ingredients across a range of platforms.

Dr Ogru added: "There are 250 million dairy cows globally and the U.S. dairy industry represents just 4% of this market.  Clearly progressing these kinds of products presents a major market opportunity for our Company."

About Phosphagenics

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® -- Targeted Penetration Matrix technology.  TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead products advancing through clinical trials are an oxycodone and oxymorphone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR -- Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com

Enquiries:

Dr Esra Ogru
Chief Executive Officer
Phosphagenics Limited
+61-3-9565-1119

David Segal
Investor Relations Manager
Phosphagenics Limited
+61-3-9565-1103

Rudi Michelson
Monsoon Communications
+61-3-9620-3333


'/>"/>
SOURCE Phosphagenics Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
2. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
3. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
4. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
5. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
6. Agendia Signs Contract with Blue Shield of California
7. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
8. Volition Signs Collaboration Agreement With Abcodia
9. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
10. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
11. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):